Navigation Links
BioLife Solutions Named One of Washington's Best Companies

BOTHELL, Wash., June 24, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTC:BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced that it has been named by Seattle Business Magazine as one of the best places to work in Washington state.



Now in its 23rd year, this competition salutes Washington companies setting the standard for leadership, strong benefits, ideal work environment, innovative training, happiest employees and more.  Winners were recognized at an awards dinner held on June 20th at the Westin Hotel in Seattle.

Mike Rice, Chief Executive Officer, commented, "Our entire team is very honored and proud to receive this recognition.  It is gratifying to see our people and special corporate culture acknowledged within the Washington state business community.  We have built a very solid, high performance team that is the single greatest contributor to the success BioLife has achieved since the Company relocated to Bothell in early 2007.  I'm honored to have the opportunity to lead such a dedicated and capable team."

In 2012, BioLife doubled revenue over 2011, doubled the size of its workforce to nearly 30 team members, and firmly established its products as best in class, clinical grade biopreservation storage and freeze media for cells, tissues, and organs.  Shares of the Company have recently traded at nearly 10 times above a previous low price set in January 2011.

Rice continued, "BioLife is a very special place to work.  A requirement for teamwork and open and honest communication is a hallmark of our merit-based culture and a foundational principal of my management philosophy."

For the complete list of winning companies, please visit:

About BioLife SolutionsBioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues.  The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce biopreservation-induced cell damage and death.  BioLife's enabling technology provides academic and clinical researchers, and commercial companies significant improvements in post-thaw cell, tissue, and organ viability and function.  For more information please visit, and follow BioLife on Twitter.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact.  Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission.  BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.  Media Relations:

Investor Relations:Len Hall

Matt ClawsonAllen & Caron Inc

Allen & Caron Inc(949) 474-4300


SOURCE BioLife Solutions, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioLife Solutions Announces Record Revenue of $2.2 Million in First Quarter of 2013
2. BioLife Solutions Announces License Agreement
3. BioLife Solutions Announces 2012 Third Quarter Results: Ninth Straight Quarter of Record Revenue
4. BioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference
5. BioLife Solutions Announces 2012 Second Quarter Results: Eighth Straight Quarter of Record Revenue
6. BioLife Solutions Completes Corporate Facilities Expansion, Build-Out of Additional cGMP Clean Room Manufacturing Suite
7. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
8. BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board
9. BioLife Solutions 2011 Revenue Up 33%
10. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
11. Accel-KKR Makes Growth Equity Investment in Zinc Ahead, Leading Provider of Marketing Compliance Solutions for the Life Sciences Industry
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... of IIROC on behalf of the Toronto Stock Exchange, ... release there are no corporate developments that would cause ... --> --> About Aeterna ... . --> Aeterna Zentaris is a ...
Breaking Biology Technology:
(Date:11/18/2015)... Nov. 18, 2015  As new scientific discoveries deepen ... and other healthcare providers face challenges in better using ... patients. In addition, as more children continue to survive ... adulthood and old age. John M. Maris, ... Hospital of Philadelphia (CHOP) . --> ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, Inc. ... the development and sale of broadly enabling, pressure cycling ... sciences industry, today announced it has received gross proceeds ... million Private Placement (the "Offering"), increasing the total amount ... or more additional closings are expected in the near ...
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
Breaking Biology News(10 mins):